Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15423548 | 0.81 | — | — | |
| SCHEMBL1985124 | 0.76 | GRM1 (0.33) | GRM1 | |
| SCHEMBL668656 | 0.76 | GRM1 (0.33) | GRM1 | |
| SCHEMBL7945360 | 0.76 | GRM1 (0.33) | GRM1 | |
| SCHEMBL13379690 | 0.76 | GRM1 (0.33) | GRM1 | |
| SCHEMBL3329472 | 0.76 | GRM2 (0.31) | GRM1 | |
| SCHEMBL789652 | 0.76 | GRM2 (0.31) | GRM1 | |
| SCHEMBL13337068 | 0.76 | GRM2 (0.31) | GRM1 | |
| Hydrochloric Acid SCHEMBL1634710 | 0.75 | GRM1 (0.33) | GRM1 | |
| SCHEMBL789448 | 0.75 | NR1H4 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010045266-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | GRM1 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.